Analytical Data
-
Gene name
STEAP1B
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6NZ63
-
Expression Region
1-245aa
-
Molecular Weight
30.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
STEAP1B (Six-Transmembrane Epithelial Antigen of the Prostate 1B) is a member of the STEAP family, which has garnered attention due to its potential role in cancer biology, particularly in prostate cancer. The STEAP proteins, characterized by multiple transmembrane domains, are involved in various cellular processes, including iron homeostasis, cell adhesion, and tumor progression. STEAP1B is believed to contribute to tumorigenesis by influencing the cellular microenvironment and modulating immune responses. Recent studies have indicated that STEAP1B may be a promising biomarker for prostate cancer diagnosis and prognosis. Additionally, the development of recombinant STEAP1B protein allows for in-depth investigation of its functional properties and interactions within the tumor microenvironment. This research leverages advanced techniques in molecular biology and protein engineering to produce STEAP1B in a recombinant form, enabling researchers to study its enzymatic activities, structural features, and potential as a therapeutic target. Understanding the mechanisms by which STEAP1B influences cancer cell behavior could provide insights into novel treatment strategies and contribute to the advancement of targeted therapies in oncology. Overall, the study of STEAP1B recombinant protein holds significant promise for enhancing our understanding of prostate cancer and improving clinical outcomes for patients.
